Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : December 18, 2017

Capitalcube gives Momenta Pharmaceuticals, Inc. a score of 36.

Our analysis is based on comparing Momenta Pharmaceuticals, Inc. with the following peers – Biogen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Amgen Inc., Johnson & Johnson, Novartis AG Sponsored ADR, Merck & Co., Inc., Pfizer Inc. and Medicines Company (BIIB-US, BMY-US, BAX-US, TEVA-US, AMGN-US, JNJ-US, NVS-US, MRK-US, PFE-US and MDCO-US).

Investment Outlook

Momenta Pharmaceuticals, Inc. has a fundamental score of 36 and has a relative valuation of NEUTRAL.

Fundamental Score

Access our research and ratings on Momenta Pharmaceuticals, Inc.

Company Overview

  • Compared to peers, relative underperformance over the last year is in contrast with the more recent outperformance.
  • It trades at a lower Price/Book multiple (2.88) than its peer median (3.99).
  • MNTA-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • MNTA-US‘s relatively low net margins and poor asset turns suggest a problematic operating strategy.
  • The company’s year-on-year change in revenues and earnings are better than the median among its peer group.
  • MNTA-US‘s return on assets currently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
  • MNTA-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful for an analysis between historical growth (using annualized three-year revenue growth) and investor growth expectations (as suggested by P/E or Price/EBITDA) .
  • The company’s capital investment program and to-date returns suggest that the company is likely making big bets on the future.
  • MNTA-US currently does not have any debt.

Access our research and ratings on Momenta Pharmaceuticals, Inc.

Leverage & Liquidity

MNTA-US currently does not have any debt.

  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 13.72%.
  • All 10 peers for the company have an outstanding debt balance.

Access the detailed analysis for Momenta Pharmaceuticals, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
Biogen Inc. 9.41 2.19 17.18 73.93
Bristol-Myers Squibb Company 7.98 1.59 25.37 73.59
Baxter International Inc. 11.64 2.8 16.99 60.73
Teva Pharmaceutical Industries Limited Sponsored ADR 60.73 0.96 4.05 13.21
Amgen Inc. 27.54 6.07 7.84 29.98
Johnson & Johnson 9.13 1.32 23.01 58.14
Novartis AG Sponsored ADR 13.72 1.08 11.62 37.82
Merck & Co., Inc. N/A 1.43 6.63 42.1
Pfizer Inc. 18.3 1.43 10.92 40.02
Medicines Company 20.54 2.31 -7.73 -50.94
Momenta Pharmaceuticals, Inc. N/A 4.16 No interest exp 999
Peer Median 13.72 1.59 11.62 42.1
Best In Class 7.98 6.07 No interest exp 999

Looking for more metrics and analysis for Momenta Pharmaceuticals, Inc.?

Company Profile

Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. The company sells its products include Glatiramer acetate injection and Enoxaparin Sodium injection. Momenta Pharmaceuticals was founded by Ram Sasisekharan and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website